Symbols

VYNE

VYNE·NASDAQ

--(--)

VYNE Profile

Vyne Therapeutics Inc.

A clinical stage bio-pharmaceutical company that developing medicines for chronic pruritus and cough

Industry

Pharmaceutical

Established Date

Listing Date

01/25/2018

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.vynetherapeutics.com

Security Type

Common stock

Office address

P.O. Box 125, Stewartsville, New Jersey 08886

Business

Introduction

VYNE Therapeutics Inc., incorporated in October 2011 as a Delaware corporation, was originally named Tigercat Pharma, Inc. The Company is a clinical-stage biopharmaceutical company focused on developing differentiated therapies for inflammatory and immune-mediated diseases with significant unmet needs. The Company has exclusive worldwide rights to research, develop and commercialize small molecule bromine domain and extra-terminal domain (BET) inhibitors licensed from Tay Therapeutics Ltd. The company targets immune-mediated inflammatory diseases and focuses on novel BET inhibitors that are not currently being developed by other companies.